| INTRODUCTION
In the United States, approximately 2.7 million persons are chronically infected with hepatitis C virus (HCV), 1 which increases the risks of developing cirrhosis and hepatocellular carcinoma. 2 Fortunately, successful treatment can lead to regression of hepatic fibrosis and reduces the likelihood of liver-related complications. 3 Historically, treatment for HCV was limited to combination therapy with the immunomodulator peginterferon and the broad-spectrum anti-viral ribavirin. Interferon and ribavirin combination regimens were long in duration, difficult to administer, poorly tolerated and frequently ineffective. The recent advent of targeted anti-virals to HCV has dramatically changed the treatment landscape, providing options for shorter, simpler and better-tolerated regimens with high likelihood of cure. 4 However, the initial direct-acting anti-viral (DAA) regimens
were not approved in certain patient subpopulations, such as those with advanced kidney disease. Patients with renal dysfunction have a higher prevalence of HCV than the general population (9.5% vs 1.6%), 5 and HCV-infected patients on hemodialysis have a higher risk of mortality vs uninfected patients. 6, 7 In January of 2016, the US Food and Drug Administration approved the fixed-dose, once-daily combination of elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor, for treating chronic HCV genotype 1 or 4 infection in adults. 8, 9 In clinical trials, elbasvir-grazoprevir with or without ribavirin for 12 or 16 weeks has shown high rates of sustained virological response (SVR) in treatment-na€ ıve or -experienced patients and has demonstrated a favourable safety profile. [10] [11] [12] [13] [14] Elbasvir-grazoprevir is metabolized in the liver vs the kidneys, and it was the first DAA regimen Platelets <100 000/lL, n/n (%) 
Total (n = 470) HCV genotype 4 n = 22 n = 1 n = 23
| Retrospective analyses
Discontinued during treatment period
Completed treatment, lost to follow-up
EBR, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; ITT, intent-to-treat; PP, per protocol; RBV, ribavirin; SVR, sustained virological response.
using the CKD-EPI Creatinine equation. 16 Patients with eGFR at baseline <90 mL/min were considered to have chronic kidney disease (CKD) Stage 2 or higher, those with ≥90 mL/min were consid- 
DAA, direct-acting anti-viral; CKD, chronic kidney disease; EBR, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; RAS, resistance-associated substitution; RBV, ribavirin; SVR, sustained virological response.
a Not all treatment-experienced patients had known prior therapies. 
| Virological response
The majority (89%) of patients received elbasvir-grazoprevir for 12 weeks (Table 2 ). Among patients with HCV genotype 1, SVR12
rates were 99% (396/402) for the per protocol population (Table 3) and 89% (396/447) for the intent-to-treat population ( 
DAA, direct-acting antiviral; CKD, chronic kidney disease; EBR, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; RAS, resistance-associated substitution; RBV, ribavirin; SVR, sustained virological response.
a Not all treatment-experienced patients had known prior therapies.
in HCV genotype 1 patients with F4 fibrosis and 100% (280/281) for those with F0-F3.
Seven patients who completed treatment did not reach SVR12
and were thus considered virological failures ( 
| Discontinuations
Based on information reported by physicians and pharmacies, 22
patients discontinued treatment; all had HCV genotype 1 infection and were receiving 12 weeks of elbasvir-grazoprevir ( Table 6 ). The most common reason for discontinuation was patient noncompliance (n = 11), followed by insurance-related issues (n = 3), medical follow-up or hospitalization unrelated to treatment (n = 3), and side effects (n = 2). For 3 patients, no reason for discontinuation was specified. None of the patients who discontinued had HBV coinfection.
Eighteen patients did not complete post-treatment follow-up visits. Again, all had HCV genotype 1 infection and were receiving 12 weeks of elbasvir-grazoprevir. None of these patients was postliver transplant or had HBV coinfection.
| Safety
Six patients died during treatment or follow-up ( In univariate analyses of the population of patients who were HCV genotype 1 and received elbasvir-grazoprevir for 12 weeks (n = 349), no variables were significantly associated with SVR12 (Table S1 ).
| DISCUSSION
In this analysis of HCV treatment in clinical practice settings, response rates to elbasvir-grazoprevir with or without ribavirin were high. Per protocol SVR12 rates were 99% for patients with HCV genotype 1 and 95% for those with HCV genotype 4. These rates are similar to those reported in clinical trials of elbasvir-grazoprevir. [10] [11] [12] [13] [14] In our study population, there were considerable numbers of patients with CKD and related co-morbidities. Almost all patients had at least profiles than interferon and ribavirin regimens, 17 and in our study, only 2 patients discontinued because of adverse events. Yet completion of treatment and follow-up visits remains problematic for some patients, as evidenced by this study and other analyses. In a realworld analysis of patients treated with elbasvir-grazoprevir in the Veterans Affairs healthcare system, 18 in which 33% had CKD stages 3-5, the per protocol SVR12 rate was 97%, similar to our per protocol rates, although our study had a higher percentage of patients with CKD stages 3-5 (43%). In the VA study, of 2985 patients who initiated treatment, 549 (18%) did not have available SVR12 data. In a real-world analysis of ledipasvir-sofosbuvir AE ribavirin, also in the Veterans Affairs healthcare system, 5.6% of patients receiving ledipasvir-sofosbuvir did not complete treatment. 19 Future analyses that more specifically address adherence and reasons for discontinuing treatment or follow-up in the era of all DAA regimens are needed.
In our cohort, the vast majority of patients (89%) received elbasvir-grazoprevir for 12 weeks, although a total of 8 different regimens were administered. Our results suggest that in clinical practice settings, elbasvir-grazoprevir is predominantly administered for 12 weeks without ribavirin, even in the presence of a baseline NS5A
RAS or history of previous usage of a protease inhibitor, and that baseline resistance testing for HCV genotype 1a patients is not universally performed. Although the SVR rate was high with nonrecommended regimens, it remains important to educate providers regarding the appropriate usage of the therapy and the need for baseline resistance testing in HCV genotype 1a patients. Educating practitioners in community settings should be a priority.
One limitation of our study is the reliance on practitioners and pharmacists to capture and report data, and therefore data capture was incomplete. For example, in some cases, treatment history or baseline resistance testing were unknown or unreported. Therefore, we do not fully know how many patients received therapy recommended by the label and how many did not.
In summary, the results of our analysis indicate that elbasvir-grazoprevir is highly effective in real-world settings for treating patients with HCV genotypes 1 or 4. In this cohort from 2016, its use was predominantly as a 12-week therapy without ribavirin.
